PMID- 25278814
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141003
LR  - 20211021
IS  - 1478-7547 (Print)
IS  - 1478-7547 (Electronic)
IS  - 1478-7547 (Linking)
VI  - 12
DP  - 2014
TI  - Cost-utility of ferric carboxymaltose (Ferinject(R)) for iron-deficiency anemia 
      patients with chronic heart failure in South Korea.
PG  - 19
LID - 10.1186/1478-7547-12-19 [doi]
AB  - BACKGROUND: Iron-deficiency anemia (IDA) is prevalent in patients with advanced 
      chronic heart failure (CHF). It affects the patients' overall physical condition 
      and is suggested as a strong outcome predictor in CHF. Recent clinical trials 
      suggested that intravenous iron supplementation improves CHF functional status 
      and quality of life. The aim of this study was to assess the cost-effectiveness 
      of ferric carboxymaltose(FCM) in CHF patients with IDA. METHODS: Ferric 
      carboxymaltose, an intravenous iron preparation, was compared with placebo. The 
      target population comprised CHF patients with IDA in hospital and outpatient care 
      settings. We conducted this study from the Korean healthcare payers' perspective 
      with a time horizon of 24 weeks. One clinical trial provided the clinical 
      outcomes of ferric carboxymaltose therapy. The improvement rates of the New York 
      Heart Association (NYHA) functional class in the placebo and ferric 
      carboxymaltose groups were used to estimate effectiveness in the base-case model. 
      We also conducted a scenario 2 analysis using quality of life investigated in the 
      clinical trial. A panel survey was conducted to obtain the ratio of healthcare 
      resource use based on NYHA class in Korea. Cost-effectiveness was expressed as 
      incremental cost (US dollars) per quality-adjusted life-year (QALY) gained. 
      RESULTS: In the base-case analysis, the incremental cost-effectiveness ratio 
      (ICER) of ferric carboxymaltose compared with placebo was $22,192 (₩25,010,451) 
      per QALY gained. The sensitivity analysis showed robust results, with the ICERs 
      of ferric carboxymaltose ranging from $5,156 to $29,796 per QALY gained. In the 
      scenario 2 analysis, ICER decreased to $12,598 (₩14,198,501) per QALY gained. 
      CONCLUSIONS: Iron repletion with ferric carboxymaltose for IDA in CHF patients 
      was cost-effective compared with placebo.
FAU - Lim, Eun-A
AU  - Lim EA
AD  - College of Pharmacy, Korea University Sejong Campus 2511 Sejong-ro, Sejong City 
      339-770, Korea.
FAU - Sohn, Hyun-Soon
AU  - Sohn HS
AD  - College of Pharmacy, Ajou University, 206 Worldcup-ro, Yeongtong-gu, Suwon-si, 
      Gyeonggi-do 443-749, Korea.
FAU - Lee, Haeyoung
AU  - Lee H
AD  - College of Pharmacy, Korea University Sejong Campus 2511 Sejong-ro, Sejong City 
      339-770, Korea.
FAU - Choi, Sang-Eun
AU  - Choi SE
AD  - College of Pharmacy, Korea University Sejong Campus 2511 Sejong-ro, Sejong City 
      339-770, Korea.
LA  - eng
PT  - Journal Article
DEP - 20140910
PL  - England
TA  - Cost Eff Resour Alloc
JT  - Cost effectiveness and resource allocation : C/E
JID - 101170476
PMC - PMC4166574
OTO - NOTNLM
OT  - Chronic heart failure
OT  - Cost utility
OT  - Cost-effectiveness
OT  - Iron-deficiency anemia
OT  - New York heart association (NYHA) functional class
EDAT- 2014/10/04 06:00
MHDA- 2014/10/04 06:01
PMCR- 2014/09/10
CRDT- 2014/10/04 06:00
PHST- 2013/11/12 00:00 [received]
PHST- 2014/06/12 00:00 [accepted]
PHST- 2014/10/04 06:00 [entrez]
PHST- 2014/10/04 06:00 [pubmed]
PHST- 2014/10/04 06:01 [medline]
PHST- 2014/09/10 00:00 [pmc-release]
AID - 1478-7547-12-19 [pii]
AID - 10.1186/1478-7547-12-19 [doi]
PST - epublish
SO  - Cost Eff Resour Alloc. 2014 Sep 10;12:19. doi: 10.1186/1478-7547-12-19. 
      eCollection 2014.